Canada Biotechnology & Medical Research

enGene Therapeutics Inc. (ENGN)

enGene Therapeutics recently recorded a single insider purchase valued at approximately $10,051. Interim Chief Medical Officer William Grossman acquired these shares on September 22, 2026. This activity follows the company's latest earnings report, which showed a significant EPS beat. The stock currently trades near its 52-week low.
Ticker: ENGN Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for enGene Therapeutics Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.4
Grossman William Interim Chief Medical Officer Executive Director
Transaction date
Purchase
Price
272.21
Quantity 4,927 +19.9%
Value US$2,542,504
3.1
Cooper Ronald Harold Wilfred Chief Executive Officer Executive Director
Transaction date
Purchase
Price
5.70
Quantity 10,000 New position
Value US$57,000
Cheung, Anthony Senior Officer of Issuer Officer
Transaction date
Purchase
Price
0.89
Quantity 52,940 +106.0%
Value US$47,117
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-24 2026-09-22 B Purchase
3.4
Grossman William

Interim Chief Medical Officer

Executive Director
4,927 +19.9%
272.21
US$2,542,504 		4,927 +19.9% 272.21 US$2,542,504
2024-11-01 2024-10-30 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
61,999 +19.9%
431.34
US$2,073,235 		61,999 +19.9% 431.34 US$2,073,235
2024-10-18 2024-10-08 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
42,467 -28.8%
486.68
US$3,667,374 		42,467 -28.8% 486.68 US$3,667,374
2024-10-18 2024-10-07 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
11,844 +0.5%
6.55
US$77,531 		11,844 +0.5% 6.55 US$77,531
2024-10-18 2024-10-04 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
5,997 +0.2%
6.54
US$39,242 		5,997 +0.2% 6.54 US$39,242
2024-10-18 2024-10-03 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
5,769 +0.2%
6.48
US$37,397 		5,769 +0.2% 6.48 US$37,397
2024-10-18 2024-10-02 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
10,153 +0.4%
6.37
US$64,697 		10,153 +0.4% 6.37 US$64,697
2024-10-18 2024-10-01 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
35,279 +1.5%
6.44
US$227,158 		35,279 +1.5% 6.44 US$227,158
2024-10-18 2024-09-30 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
341,332 +16.6%
6.34
US$2,163,362 		341,332 +16.6% 6.34 US$2,163,362
2024-10-18 2024-09-27 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
3,243 +0.2%
6.38
US$20,688 		3,243 +0.2% 6.38 US$20,688
2024-10-18 2024-09-27 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
38,396 +1.9%
5.94
US$228,011 		38,396 +1.9% 5.94 US$228,011
2024-10-01 2024-09-27 B Purchase
3.1
Cooper Ronald Harold Wilfred

Chief Executive Officer

Executive Director
10,000 New position
5.70
US$57,000 		10,000 New position 5.70 US$57,000
2024-04-22 2024-04-22 S Sale
3.8
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
Large shareholder
47,854 -1.6%
15.00
US$717,810 		47,854 -1.6% 15.00 US$717,810
2024-04-22 2024-04-19 S Sale
3.8
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
Large shareholder
100 -0.0%
15.00
US$1,500 		100 -0.0% 15.00 US$1,500
2024-04-22 2024-04-18 S Sale
3.8
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
Large shareholder
4,575 -0.1%
15.01
US$68,671 		4,575 -0.1% 15.01 US$68,671
2024-03-20 2024-03-18 B Purchase
Cheung, Anthony

Senior Officer of Issuer

Officer
52,940 +106.0%
0.89
US$47,117 		52,940 +106.0% 0.89 US$47,117
2024-10-18 2023-12-29 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
9,620 +0.5%
9.09
US$87,451 		9,620 +0.5% 9.09 US$87,451
2024-10-18 2023-12-29 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
400 +0.0%
8.30
US$3,320 		400 +0.0% 8.30 US$3,320
2024-10-18 2023-12-28 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
5,050 +0.3%
7.69
US$38,827 		5,050 +0.3% 7.69 US$38,827
2024-10-18 2023-12-27 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
2,750 +0.1%
7.17
US$19,711 		2,750 +0.1% 7.17 US$19,711
Explore more

More insider trading research around enGene Therapeutics Inc.

More insider trades in Canada
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America